Mutant p53 drives cancer by subverting multiple tumor suppression pathways

Frontiers in Oncology

Volumn 6, Issue JAN, 2016, Pages

  Haupt, Sue ^a,b   Raghu, Dinesh ^a,b   Haupt, Ygal ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Cell cycle; Gain of function; Metabolism; P53 mutations; Transcriptional regulation

Indexed keywords

GLUCOSE TRANSPORTER 1; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEAR FACTOR Y; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLO LIKE KINASE 2; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR SNF;

CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL SURVIVAL; DNA DAMAGE; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; NUCLEOTIDE METABOLISM; OXIDATION; PROMYELOCYTIC LEUKEMIA; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84958165181     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00012     Document Type: Review

References (58)

1. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 2(2):a001107. doi:10.1101/cshperspect.a001107
2. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, et al. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res (2009) 69(11):4818-26. doi:10.1158/0008-5472.CAN-08-4010
3. Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y. PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene (2008) 27(26):3653-61. doi:10.1038/sj.onc.1211036
4. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, PandolfiPP, Haupt Y. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem (2003) 278(35):33134-41. doi:10.1074/jbc. M301264200
5. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Droge W, et al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res (2003) 63(15):4310-4.
6. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 406(6792):207-10. doi:10.1038/35018127
7. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A (2013) 110(10):3895-900. doi:10.1073/pnas.1300490110
8. de Stanchina E, Querido E, Narita M, Davuluri RV, PandolfiPP, Ferbeyre G, et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 13(4):523-35. doi:10.1016/S1097-2765(04)00062-0
9. Kiesslich A, von Mikecz A, Hemmerich P. Cell cycle-dependent association of PML bodies with sites of active transcription in nuclei of mammalian cells. J Struct Biol (2002) 140(1-3):167-79. doi:10.1016/S1047-8477(02)00571-3
10. Bernardi R, PandolfiPP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene (2003) 22(56):9048-57. doi:10.1038/sj.onc.1207106
11. PandolfiPP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, et al. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J (1992) 11(4):1397-407.
12. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 10(3):191-202. doi:10.1016/j.ccr.2006.08.013
13. Di Agostino S, Strano S, Blandino G. Gender, mutant p53 and PML: a growing "affaire" in tumor suppression and oncogenesis. Cell Cycle (2013) 12(12):1824-5. doi:10.4161/cc.25174
14. Tan XM, Ye H, Yang K, Chen D, Wang QQ, Tang H, et al. Circadian variations of clock gene Per2 and cell cycle genes in different stages of carcinogenesis in golden hamster buccal mucosa. Sci Rep (2015) 5:9997. doi:10.1038/srep09997
15. Miki T, Matsumoto T, Zhao Z, Lee CC. p53 regulates period2 expression and the circadian clock. Nat Commun (2013) 4:2444. doi:10.1038/ncomms3444
16. Miki T, Xu Z, Chen-Goodspeed M, Liu M, Van Oort-Jansen A, Rea MA, et al. PML regulates PER2 nuclear localization and circadian function. EMBO J (2012) 31(6):1427-39. doi:10.1038/emboj.2012.1
17. Grechez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem (2008) 283(8):4535-42. doi:10.1074/jbc. M705576200
18. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer (2009) 9(12):886-96. doi:10.1038/nrc2747
19. Gu X, Xing L, Shi G, Liu Z, Wang X, Qu Z, et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ (2012) 19(3):397-405. doi:10.1038/cdd.2011.103
20. Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, PandolfiPP, et al. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle (2013) 12(11):1722-31. doi:10.4161/cc.24805
21. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res (2010) 49(1):60-8. doi:10.1111/j.1600-079X.2010.00767.x
22. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene (2008) 27(41):5443-53. doi:10.1038/onc.2008.241
23. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell (2003) 3(2):117-30. doi:10.1016/S1535-6108(03)00021-7
24. Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res (2008) 68(6):1723-31. doi:10.1158/0008-5472.CAN-07-1963
25. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell (2001) 8(2):317-25. doi:10.1016/S1097-2765(01)00323-9
26. Huang X, Zhang Y, Tang Y, Butler N, Kim J, Guessous F, et al. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. Neoplasia (2013) 15(8):952-65. doi:10.1593/neo.13376
27. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 23(16):5556-71. doi:10.1128/MCB.23.16.5556-5571.2003
28. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, et al. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle (2011) 10(24):4330-40. doi:10.4161/cc.10.24.18682
29. Haupt S, Haupt Y. Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption. Cell Cycle (2012) 11(2):217-8. doi:10.4161/cc.11.2.18977
30. Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, et al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun (2015) 6:7389. doi:10.1038/ncomms8389
31. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2010) 2(4):a001040. doi:10.1101/cshperspect.a001040
32. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res (2004) 64(7):2627-33. doi:10.1158/0008-5472.CAN-03-0846
33. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 126(1):107-20. doi:10.1016/j.cell.2006.05.036
34. Wang YC, Lee HS, Chen SK, Yang SC, Chen CY. Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. J Cancer Res Clin Oncol (1998) 124(9):517-22. doi:10.1007/s004320050208
35. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol (2011) 13(3):310-6. doi:10.1038/ncb2172
36. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun (2013) 4:2935. doi:10.1038/ncomms3935
37. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle (2012) 11(23):4436-46. doi:10.4161/cc.22778
38. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr (2013) 67(8):789-96. doi:10.1038/ejcn.2013.116
39. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med (2015) 66:17-29. doi:10.1146/annurev-med-062613-093128
40. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest (2002) 109(9):1125-31. doi:10.1172/JCI15593
41. Yahagi N, Shimano H, Matsuzaka T, Najima Y, Sekiya M, Nakagawa Y, et al. p53 activation in adipocytes of obese mice. J Biol Chem (2003) 278(28):25395-400. doi:10.1074/jbc. M302364200
42. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 148(1-2):244-58. doi:10.1016/j.cell.2011.12.017
43. Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol (2014) 25:23-32. doi:10.1016/j.semcancer.2013.12.007
44. Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, et al. Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein. J Biol Chem (2012) 287(9):6539-50. doi:10.1074/jbc. M111.316471
45. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell (2009) 34(6):663-73. doi:10.1016/j.molcel.2009.04.029
46. Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ (2010) 17(1):103-8. doi:10.1038/cdd.2009.67
47. Asher G, Lotem J, Tsvetkov P, Reiss V, Sachs L, Shaul Y. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc Natl Acad Sci U S A (2003) 100(25):15065-70. doi:10.1073/pnas.2436329100
48. Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J Cell Sci (2012) 125(22):5578-86. doi:10.1242/jcs.106815
49. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 25(1):47-54. doi:10.1038/75586
50. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 3(4):387-402. doi:10.1016/S1535-6108(03)00079-5
51. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol (2013) 15(1):2-8. doi:10.1038/ncb2641
52. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ (2006) 13(6):951-61. doi:10.1038/sj.cdd.4401916
53. Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem (2002) 277(25):22330-7. doi:10.1074/jbc. M111987200
54. Xu Y, Zhang J, Chen X. The activity of p53 is differentially regulated by Brm-and Brg1-containing SWI/SNF chromatin remodeling complexes. J Biol Chem (2007) 282(52):37429-35. doi:10.1074/jbc. M706039200
55. Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev (2015) 29(12):1298-315. doi:10.1101/gad.263202.115
56. Kim S, Balakrishnan SK, Gross DS. p53 interacts with RNA polymerase II through its core domain and impairs Pol II processivity in vivo. PLoS One (2011) 6(8):e22183. doi:10.1371/journal.pone.0022183
57. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev (2012) 26(8):830-45. doi:10.1101/gad.181685.111
58. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature (2015) 525(7568):206-11. doi:10.1038/nature15251